Immunohistochemistry (IHC) analyses of specimens collected from various tumors, outside of this clinical trial, revealed LAG-3+ expression in most cancers, with frequency ranging from 52% (small cell lung cancer (SCLC)) to 100% (cervical cancer) (Supplementary Fig. 1a). Here, LAG3 is linked to cervical carcinoma.